Compare Adaptive Biotechnologies Corp (ADPT) vs EPAM Systems Inc (EPAM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs EPAM Systems Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while EPAM Systems Inc trades at $87.51 (market cap $4.68B). The key difference: EPAM Systems Inc is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, EPAM Systems Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | EPAM | |
|---|---|---|
Market Cap | $3.33B | $4.68B |
Sector | Health | Technology |
52-Week High | $22.37 | $221.40 |
52-Week Low | $10.24 | $76.04 |
Enterprise Value | $3.19B | $3.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
EPAM Systems trades at $89.55, up 1.45% today, with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics with a P/E of 12.48 and P/S of 0.87, while revenue grew to $5.46B in 2025. Recent news highlights EPAM's AI partnership successes and upcoming Q2 2026 earnings, with analyst consensus strongly favoring Buy ratings (64.87%) and a $130.90 price target suggesting significant upside.
The outlook remains positive given EPAM's solid fundamentals and AI-driven growth, but risks include competitive pressures in IT services and market volatility. Institutional sentiment is bullish, though technical indicators warn of near-term resistance. Investors should weigh the strong analyst support against recent price weakness and sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →
